Edgewise Therapeutics, Inc. Research and Development Expense
Edgewise Therapeutics, Inc. (EWTX) reported Research and Development Expense of $47.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Edgewise Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $47.55M, a 41.69% increase year-over-year.
- Edgewise Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $42.65M, a 16.04% increase year-over-year.
- Edgewise Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $43.59M, a 19.86% increase year-over-year.
- Edgewise Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $37.48M, a 16.32% increase year-over-year.
- Edgewise Therapeutics, Inc. research and development expense for fiscal 2025 was $151.39M, a 19.24% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. research and development expense for fiscal 2024 was $126.97M, a 39.67% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. research and development expense for fiscal 2023 was $90.91M, a 68.24% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. research and development expense for fiscal 2022 was $54.03M, a 67.86% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.55M 10-Q · filed 2026-08-06 | $90.20M 10-Q · filed 2026-08-06 | $133.79M derived: sum of 3 quarters · filed 2026-08-06 | $171.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $42.65M 10-Q · filed 2026-05-07 | $86.25M derived: sum of 2 quarters · filed 2026-05-07 | $123.72M derived: sum of 3 quarters · filed 2026-05-07 | $157.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $43.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $81.07M derived: sum of 2 quarters · filed 2026-02-26 | $114.63M derived: sum of 3 quarters · filed 2026-08-06 | $151.39M 10-K · filed 2026-02-26 |
| 2025-09-30 | $37.48M 10-Q · filed 2025-11-06 | $71.04M derived: sum of 2 quarters · filed 2026-08-06 | $107.80M 10-Q · filed 2025-11-06 | $144.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $33.56M 10-Q · filed 2026-08-06 | $70.31M 10-Q · filed 2026-08-06 | $106.69M derived: sum of 3 quarters · filed 2026-08-06 | $138.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $36.76M 10-Q · filed 2026-05-07 | $73.13M derived: sum of 2 quarters · filed 2026-05-07 | $105.35M derived: sum of 3 quarters · filed 2026-05-07 | $136.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $36.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $68.59M derived: sum of 2 quarters · filed 2026-02-26 | $99.27M derived: sum of 3 quarters · filed 2026-02-26 | $126.97M 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.22M 10-Q · filed 2025-11-06 | $62.90M derived: sum of 2 quarters · filed 2025-11-06 | $90.60M 10-Q · filed 2025-11-06 | $118.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $30.68M 10-Q · filed 2025-08-07 | $58.37M 10-Q · filed 2025-08-07 | $86.06M derived: sum of 3 quarters · filed 2026-02-26 | $109.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $27.69M 10-Q · filed 2025-05-08 | $55.38M derived: sum of 2 quarters · filed 2026-02-26 | $79.16M derived: sum of 3 quarters · filed 2026-02-26 | $98.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $27.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $51.47M derived: sum of 2 quarters · filed 2026-02-26 | $71.03M derived: sum of 3 quarters · filed 2026-02-26 | $90.91M 10-K · filed 2026-02-26 |
| 2023-09-30 | $23.79M 10-Q · filed 2024-11-07 | $43.34M derived: sum of 2 quarters · filed 2024-11-07 | $63.22M 10-Q · filed 2024-11-07 | $79.83M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $19.56M 10-Q · filed 2024-08-08 | $39.44M 10-Q · filed 2024-08-08 | $56.05M derived: sum of 3 quarters · filed 2024-08-08 | $69.94M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $19.88M 10-Q · filed 2024-05-09 | $36.49M derived: sum of 2 quarters · filed 2024-05-09 | $50.38M derived: sum of 3 quarters · filed 2024-05-09 | $62.78M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $16.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $30.51M derived: sum of 2 quarters · filed 2024-02-22 | $42.91M derived: sum of 3 quarters · filed 2024-02-22 | $54.03M 10-K · filed 2024-02-22 |
| 2022-09-30 | $13.89M 10-Q · filed 2023-11-09 | $26.30M derived: sum of 2 quarters · filed 2023-11-09 | $37.42M 10-Q · filed 2023-11-09 | $46.51M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $12.40M 10-Q · filed 2023-08-10 | $23.53M 10-Q · filed 2023-08-10 | $32.61M derived: sum of 3 quarters · filed 2023-08-10 | $42.49M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $11.12M 10-Q · filed 2023-05-11 | $20.21M derived: sum of 2 quarters · filed 2023-05-11 | $30.09M derived: sum of 3 quarters · filed 2023-05-11 | $37.95M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $9.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $18.97M derived: sum of 2 quarters · filed 2023-02-23 | $26.83M derived: sum of 3 quarters · filed 2023-02-23 | $32.19M 10-K · filed 2023-02-23 |
| 2021-09-30 | $9.88M 10-Q · filed 2022-11-03 | $17.74M derived: sum of 2 quarters · filed 2022-11-03 | $23.10M 10-Q · filed 2022-11-03 | $28.24M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $7.86M 10-Q · filed 2022-08-04 | $13.22M 10-Q · filed 2022-08-04 | $18.36M derived: sum of 3 quarters · filed 2022-08-04 | $21.60M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $5.36M 10-Q · filed 2022-05-11 | $10.50M derived: sum of 2 quarters · filed 2022-05-11 | $13.74M derived: sum of 3 quarters · filed 2022-05-11 | $17.38M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $8.38M derived: sum of 2 quarters · filed 2022-02-24 | $12.02M derived: sum of 3 quarters · filed 2022-02-24 | $14.98M 10-K · filed 2022-02-24 |
| 2020-09-30 | $3.24M 10-Q · filed 2021-11-10 | $6.88M derived: sum of 2 quarters · filed 2021-11-10 | $9.84M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.64M 10-Q · filed 2021-08-09 | $6.61M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $2.97M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |